Cannassure Therapeutics (TASE: CSURE) announces another company milestone as they successfully complete their medical cannabis analytical method development and validation, in accordance with IMCA requirements. The activity was conducted in the company’s laboratory, led by Dana Marom, VP QA, and performed by the highly skilled Cannassure R&D and QA teams, accompanied by a GSAP regulatory consulting team.

The analysis and validation methods developed, identify seven cannabinoids-THC and CBD and their derivatives THCA and CBDA, as well as CBN, CBC and CBG.  The cannabinoids can be detected in cannabis flowers, extracts, and tinctures to ensure quality, stability and consistency of Cannassure’s products and meet GMP and other regulatory requirements and specifications for the pharmaceutical industry.

“Cannassure has the knowhow to conduct our own testing of cannabis and medical cannabis products in a fast and reliable manner, without the need of external suppliers. This is completely in line with the company’s strategy of establishing a holistic medical cannabis production facility.  Our vertically integrated operation will include advanced agritech breeding, an indoor grow operation, a state-of-the-art extraction and processing facility, together with scientifically advanced R&D,” states Ran Amir, Cannassure CEO.

SOURCE Cannassure Therapeutics